Rhodopsin crystal: New template yielding realistic models of G-protein-coupled receptors?

Trends in Pharmacological Sciences

Volumn 24, Issue 1, 2003, Pages 36-40

  Archer, Elodie ^a   Maigret, Bernard ^b   Escrieut, Chantal ^a   Pradayrol, Lucien ^a   Fourmy, Daniel ^a  

^a CHU RANGUEIL   (France)

^b NANCY UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (4 CHLORO 2,5 DIMETHOXYPHENYL) 5 (2 CYCLOHEXYLETHYL)THIAZOL 2 YLCARBAMOYL] 5,7 DIMETHYLINDOL 1 YL 1 ACETIC ACID; ACETIC ACID DERIVATIVE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; DEVAZEPIDE; G PROTEIN COUPLED RECEPTOR; LINTITRIPT; RHODOPSIN; SR 146131; UNCLASSIFIED DRUG;

CRYSTALLIZATION; EXPERIMENTAL MODEL; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY;

ANIMALS; CRYSTALLIZATION; GTP-BINDING PROTEINS; HUMANS; MODELS, MOLECULAR; RECEPTORS, CELL SURFACE; RHODOPSIN;

EID: 0037215651     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)00009-3     Document Type: Review

References (40)

1. Bockaert J., Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18:1999;1723-1729.
2. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964.
3. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921.
4. Venter J.C., et al. The sequence of the human genome. Science. 291:2001;1304-1351.
5. Takeda S., et al. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 520:2002;97-101.
6. Wise A., et al. Target validation of G-protein coupled receptors. Drug Discov. Today. 7:2002;235-246.
7. Howard A.D., et al. Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol. Sci. 22:2001;132-140.
8. Palczewski K., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 289:2000;739-745.
9. Bajorath J. Rational drug discovery revisited: interfacing experimental programs with bio- and chemo-informatics. Drug Discov. Today. 6:2001;989-995.
10. Henderson R., Unwin P.N. Three-dimensional model of purple membrane obtained by electron microscopy. Nature. 257:1975;28-32.
11. Schertler G.F., Hargrave P.A. Projection structure of frog rhodopsin in two crystal forms. Proc. Natl Acad. Sci. USA. 92:1995;11578-11582.
12. Unger V.M., et al. Arrangement of rhodopsin transmembrane α-helices. Nature. 389:1997;203-206.
13. Baldwin J.M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12:1993;1693-1703.
14. Campagne F., et al. Visualisation and integration of G protein-coupled receptor related information help the modelling: description and applications of the Viseur program. J. Comput. Aided Mol. Des. 13:1999;625-643.
15. Meng E.C., Bourne H.R. Receptor activation: what does the rhodopsin structure tell us? Trends Pharmacol. Sci. 22:2001;587-593.
16. Okada T., et al. Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem. Sci. 26:2001;318-324.
17. Ballesteros J.A., et al. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60:2001;1-19.
18. Lu Z.L., et al. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 23:2002;140-146.
19. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16:1988;10881-10890.
20. Poirot S.S., et al. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor. Mol. Pharmacol. 45:1994;599-607.
21. Kennedy K., et al. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. J. Biol. Chem. 272:1997;2920-2926.
22. Gigoux V., et al. Met-195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state. J. Biol. Chem. 273:1998;14380-14386.
23. Gigoux V., et al. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C- terminal amide of cholecystokinin. J. Biol. Chem. 274:1999;20457-20464.
24. Gigoux V., et al. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin. Protein Sci. 8:1999;2347-2354.
25. Gouldson P., et al. Contrasting roles of leu(356) in the human CCK(1) receptor for antagonist SR 27897 and agonist SR 146131 binding. Eur. J. Pharmacol. 383:1999;339-346.
26. Gouldson P., et al. Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S. Eur. J. Pharmacol. 389:2000;115-124.
27. Escrieut C., et al. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process. J. Biol. Chem. 277:2002;7546-7555.
28. Ding X.Q., et al. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol. Pharmacol. 61:2002;1041-1052.
29. Pellegrini M., Mierke D.F. Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy. Biochemistry. 38:1999;14775-14783.
30. Giragossian C., Mierke D.F. Intermolecular Interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin A receptor. Biochemistry. 40:2001;3804-3809.
31. Smeets R.L., et al. Mutational analysis of the putative devazepide binding site of the CCK(A) receptor. Eur. J. Pharmacol. 325:1997;93-99.
32. Gershengorn M.C., Osman R. Minireview: insights into G protein-coupled receptor function using molecular models. Endocrinology. 142:2001;2-10.
33. Marie J., et al. Control of conformational equilibria in the human B2 bradykinin receptor. Modeling of nonpeptidic ligand action and comparison to the rhodopsin structure. J. Biol. Chem. 276:2001;41100-41111.
34. Shin N., et al. Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine h(4) receptor. Mol. Pharmacol. 62:2002;38-47.
35. Manivet P., et al. The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis. J. Biol. Chem. 277:2002;17170-17178.
36. Sakmar T.P. Structure of rhodopsin and the superfamily of seven-helical receptors: the same and not the same. Curr. Opin. Cell Biol. 14:2002;189-195.
37. Chung D.A., et al. NMR structure of the second intracellular loop of the α2A adrenergic receptor: evidence for a novel cytoplasmic helix. Biochemistry. 41:2002;3596-3604.
38. Zhang L., et al. NMR and modeling studies of a synthetic extracellular loop II of the kappa opioid receptor in a DPC micelle. Biochemistry. 41:2002;61-68.
39. Silvente-Poirot S., et al. Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor. J. Biol. Chem. 274:1999;23191-23197.
40. Elling C.E., Schwartz T.W. Connectivity and orientation of the seven helical bundle in the tachykinin NK-1 receptor probed by zinc site engineering. EMBO J. 15:1996;6213-6219.